Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nanosphere Health SciencesNSHSF 3-Year EBITDA Growth Rate is 33.80% as of Dec. 2025, which is 24% below its 10-year median of 44.40. Among 1,129 Biotechnology companies, Nanosphere Health Sciences ranks better than 71.66% on this metric.
During the past 12 months, Nanosphere Health Sciences's average EBITDA Per Share Growth Rate was -129.70% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 33.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Nanosphere Health Sciences was 82.20% per year. The lowest was -188.40% per year. And the median was 44.40% per year.
Nanosphere Health Sciences (OTCPK:NSHSF) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Nanosphere Health Sciences 3-Year EBITDA Growth Rate Related Terms
NSHSF vs VRTX, REGN, RVMD: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Nanosphere Health Sciences's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nanosphere Health Sciences 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nanosphere Health Sciences's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Nanosphere Health Sciences's 3-Year EBITDA Growth Rate falls into.
Nanosphere Health Sciences 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 33.80% mean?
Nanosphere Health Sciences (NSHSF) has a 3-Year EBITDA Growth Rate of 33.80% as of Dec. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Nanosphere Health Sciences and its competitors. This is 24% below median its historical median of 44.40. According to the industry distribution chart, Nanosphere Health Sciences ranks #320 out of 1129 companies in the Biotechnology industry, placing it in the top 28.3%.
Is Nanosphere Health Sciences' 3-Year EBITDA Growth Rate too high?
Nanosphere Health Sciences' current 3-Year EBITDA Growth Rate of 33.80% is 24% below median its 10-year median of 44.40. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.70. Nanosphere Health Sciences' value of 33.80% is 129.9% above this industry median. Based on the distribution chart, Nanosphere Health Sciences ranks #320 out of 1129 companies in the Biotechnology industry, which is above the industry midpoint.
How does Nanosphere Health Sciences' 3-Year EBITDA Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Nanosphere Health Sciences ranks #320 out of 1129 companies for 3-Year EBITDA Growth Rate. This puts Nanosphere Health Sciences in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.70. Nanosphere Health Sciences' value of 33.80% is 129.9% above this benchmark. While the company's 10-year median is 44.40 vs. the industry median of 14.70, Nanosphere Health Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.70, based on 1,129 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nanosphere Health Sciences's current 3-Year EBITDA Growth Rate of 33.80% is 129.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Nanosphere Health Sciences and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nanosphere Health Sciences's current 3-Year EBITDA Growth Rate is 33.80%, which is 24% below median its own 10-year median of 44.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nanosphere Health Sciences stock overvalued right now?
Nanosphere Health Sciences (NSHSF) has a current 3-Year EBITDA Growth Rate of 33.80%. The current 3-Year EBITDA Growth Rate is 33.80%, which is 24% below median its 10-year median of 44.40 and 129.9% above the Biotechnology industry median of 14.70. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Nanosphere Health Sciences (NSHSF), the current 3-Year EBITDA Growth Rate is 33.80% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Nanosphere Health Sciences Inc is a biotechnology company focused on providing next generation delivery of biologically active compounds through licensing and joint venture arrangements. The Company has developed and is commercializing its patented NanoSphere Delivery System, a nanotechnology platform for the delivery of biological agents such as cannabinoids, supplements, nutraceuticals, and over-the-counter medications for the cannabis, pharmaceutical, and animal health industries. The NanoSphere Delivery System provides improved bioavailability, efficacy, and onset of effect over traditional delivery systems.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSHSF has been successfully added to your 
